Table 3.

All cycles grade 3/grade 4 adverse events at least possibly related to treatment

Patients with at least oneCycle 1, n (%)*All cycles, n (%)*
Any grade 3+ toxicity13 (34.2%)16 (42.1%)
Any grade 4+ toxicity1 (2.6%)1 (2.6%)
Grade 3+ heme toxicity5 (13.2%)6 (15.8%)
Grade 4+ heme toxicity
Grade 3+ nonheme toxicity9 (23.7%)11 (28.9%)
Grade 4+ nonheme toxicity1 (2.6%)1 (2.6%)
Toxicities
Grade 3
Grade 4
Grade 3
Grade 4
Hematologic
    Neutropenia3 (7.9%)5 (13.2%)
    Leukopenia2 (5.3%)2 (5.3%)
    Anemia1 (2.6%)
    Thrombocytopenia2 (5.3%)2 (5.3%)
Nonhematologic
    Dehydration2 (5.3%)2 (5.3%)
    Rash1 (2.6%)1 (2.6%)
    Diarrhea3 (7.9%)4 (10.5%)
    Fatigue4 (10.5%)5 (13.2%)
    Febrile neutropenia1 (2.6%)1 (2.6%)
    Nausea4 (10.5%)4 (10.5%)
    Vomiting3 (7.9%)3 (7.9%)
  • * Out of a total of 37 patients evaluable for toxicity.

  • The same patient could have multiple toxicities.